Craig Coleman
Professor/Pharmacy Practice
Storrs Mansfield
Are you Craig Coleman?
How to update your information.
Scholarly Contributions
620 Scholarly Contributions
Cost-Effectiveness of Olorofim in Invasive Aspergillosis Patients Lacking Suitable Alternative Treatment Options from a US Payer Perspective. ISPOR 2024, May 2024.
2024
Research Type: Poster/Presentation
Abstract WP231: The Incidence of Intracranial Hemorrhage in Patients Anticoagulated With Factor Xa Inhibitors (FXai): A Multi-Country Observational Study (AXIOM ICH).
2024
Research Type: Poster/Presentation
Effectiveness of High- Versus Low-Dose Four-Factor Prothrombin Complex Concentrate on Hemostasis and Thromboembolism in Patients with Oral Factor Xa Inhibitor-Associated Intracranial Hemorrhage
2023
Research Type: Poster/Presentation
High risk of bias in studies assessing reversal and replenishment replacement agents for factor Xa inhibitor bleeding.
2023
Research Type: Poster/Presentation
COMPARATIVE EFFECTIVENESS AND SAFETY OUTCOMES OF REDUCED DOSE DOACS VS WARFARIN: A MULTINATIONAL COHORT STUDY OF INDIVIDUALS WITH AF
2023
Research Type: Poster/Presentation
PB1110 Implementation of International Society on Thrombosis and Haemostasis Definitions of Major and Clinically Relevant Non-Major Bleed Events in Electronic Health Records
2023
Research Type: Poster/Presentation
Comparison of VTE recurrence, bleeding-related hospitalization and all-cause mortality in patients with active cancer in two patient populations, based upon cancer types …
2023
Research Type: Poster/Presentation
OC 54.1 Effectiveness and Safety of Rivaroxaban and Low Molecular-Weight Heparin in Cancer-Associated Venous Thromboembolism: A Meta-Analysis of Oscar Programme Findings.
2023
Research Type: Poster/Presentation
Effectiveness of high-versus low-dose four-factor prothrombin complex concentrate on hemostasis and thromboembolism in patients with oral factor Xa inhibitor-associated
2023
Research Type: Poster/Presentation
PERSISTENCE OF REDUCED DOSE DOACS AND WARFARIN: A MULTINATIONAL COHORT STUDY OF INDIVIDUALS WITH INCIDENT AF
2023
Research Type: Poster/Presentation
2 Lower In-Hospital Mortality and Rebleeding Among Patients With Major Gastrointestinal Bleeding Treated With Andexanet Alfa vs 4-Factor Prothrombin Complex Concentrate. G Fermann, C Coleman, M Danese, E Lesén, M Christoph, R Chang,
2023
Research Type: Poster/Presentation
A Meta-Analysis of High-Dose Versus Low-Dose 4-Factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitor-Associated Intracerebral Hemorrhage
2023
Research Type: Poster/Presentation
A quality assessment of meta-analyses evaluating andexanet alfa and prothrombin complex concentrate (PCC) products.
2023
Research Type: Poster/Presentation
Using 30-Day Modified Rankin Scale Score to Predict 90-Day Values in Individuals With Intracerebral Hemorrhage
2023
Research Type: Poster/Presentation
OC 31.2 Andexanet Alfa is Associated with Lower In-Hospital Mortality Compared to 4-Factor Prothrombin Complex Concentrate in Patients with Factor Xa Inhibitor–Related Major
2023
Research Type: Poster/Presentation
A meta-analysis of high-dose versus low-dose 4-factor prothrombin complex concentrate for reversal of factor Xa inhibitor-associated intracerebral hemorrhage
2023
Research Type: Poster/Presentation
Derivation and validation of the saved score for prediction of unfavorable modified Rankin scale score following intracerebral hemorrhage.
2022
Research Type: Poster/Presentation
Rivaroxaban Versus Apixaban for Treatment of Cancer-Associated Venous Thromboembolism: A Head-to-Head Analysis of the United States Cohort of the Observational Study in Cancer …
2022
Research Type: Poster/Presentation
Meta-Analysis and Meta-Regression to Assess Four-Factor Prothrombin Complex Concentrate's Ability to Achieve Hemostatic Effectiveness in Patients with Oral Factor Xa Inhibitor …
2022
Research Type: Poster/Presentation